Effect of (+)-cyanidanol-3 in acute HAV, HBV, and non-A, non-B viral hepatitis.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001578:Benzopyrans / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D002392:Catechin / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006511:Hepatitis B Antigens / Q000032:analysis; D006526:Hepatitis C / Q000188:drug therapy; D006525:Hepatitis, Viral, Human / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013997:Time Factors
D001578:Benzopyrans; D006511:Hepatitis B Antigens; D002392:Catechin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin